Neutrophil is an important part of the innate immune system,and the dysfunction of neutrophil is closely related to many diseases.Dipeptidyl peptidase Ⅰ is a lysosomal cysteine protease that mediates neutrophil associated inflammatory processes.Dipeptidyl peptidase Ⅰ plays a key role in various inflammatory diseases,and has become a novel target for the development of therapeutic drug for inflammatory diseases.In this paper,the research progress of dipeptidyl peptidase Ⅰ inhibitors is summarized from three aspects:experience-based drug design,target-based rational design,and new selection of target design site,aiming to provide references for the development of novel high-efficiency,low-toxicity dipeptidyl peptidase Ⅰ inhibitors.
NETL
NSTL
万方数据
